Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
9.20
+0.22 (2.45%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.87 - 9.28
52 week 6.40 - 15.82
Open 9.05
Vol / Avg. 0.00/311,761.00
Mkt cap 261.24M
P/E     -
Div/yield     -
EPS -3.34
Shares 28.40M
Beta 0.27
Inst. own 79%
Aug 4, 2014
Q2 2014 Heron Therapeutics Inc Earnings Release- Tentative Add to calendar
Jun 25, 2014
Heron Therapeutics Inc at JMP Securities Healthcare Conference
Jun 2, 2014
Heron Therapeutics Inc at Jefferies Global Healthcare Conference - Webcast
May 14, 2014
Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 8, 2014
Q1 2014 Heron Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -101.41% -83.82%
Return on average equity -113.14% -91.56%
Employees 47 -
CDP Score - -

Address

123 SAGINAW DRIVE
REDWOOD CITY, CA 94063
United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heron Therapeutics Inc, formerly A.P. Pharma, Inc. is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company�s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company�s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Robert H. Rosen President, Director
Age: 58
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mark S. Gelder M.D. Senior Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 53
Bio & Compensation  - Reuters
Craig A. Johnson Independent Director
Age: 53
Bio & Compensation  - Reuters
Kimberly J. Manhard Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Poyhonen Independent Director
Age: 54
Bio & Compensation  - Reuters